Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia

Waldenström's Macroglobulinemia Clinical Trial

Official title:
iNNOVATE Study: A Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects With Waldenström's Macroglobulinemia

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of ibrutinib in combination with rituximab in participants with Waldenström's macroglobulinemia (WM).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02165397
Study type	Interventional
Source	Pharmacyclics LLC.
Contact
Status	Completed
Phase	Phase 3
Start date	July 7, 2014
Completion date	November 7, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00398710` - A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia	Phase 2
Completed	`NCT01788020` - Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia	Phase 3
Recruiting	`NCT03697356` - R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia	Phase 2
Completed	`NCT03053440` - A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)	Phase 3
Recruiting	`NCT05979948` - A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia	Phase 2
Recruiting	`NCT05326308` - Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma